CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–AmerisourceBergen, a global healthcare solutions company, today announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will invest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals globally. AB Health Ventures will build on AmerisourceBergen’s ongoing commitment to delivering innovation for its customers.
The impacts of various ongoing developments, from the metaverse’s increasing prominence to the forthcoming gubernatorial shift, on Maryland’s tech economy were on the minds of attendees and panelists alike at last Thursday’s Digital Transformation Summit.
The Maryland Tech Council hosted its third iteration of the annual convention, in which the economic development group looks at the Maryland tech economy’s future, at the Maryland Jockey Club in Laurel.
Image: (L to R) Fearless’ design director Jordan Watts; Exelon’s principal product designer Chris-Anne Correa; Mindgrub’s research and experience design director Shannon Hosmer; Christine Jackson, director of digital Strategy for the National Aquarium; and Solomon Scott, engineering lead, for The Washington Post, speak on a panel during the third annual Digital Transformation Summit. – https://technical.ly
GERMANTOWN, Md., April 6, 2022 /PRNewswire/ — BiOneCure Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the IND for BIO-106, an antibody-drug conjugate (ADC) designed to target TROP-2 to treat a broad range of advanced solid tumors.
The clinical study cleared by the FDA, known as StarBridge-1, is a Phase I/II, multicenter, open-label study to evaluate the safety, pharmacokinetics and preliminary anti-tumor activity of BIO-106 as monotherapy and in combination with pembrolizumab in patients with advanced cancers.
John Newby is CEO of Virginia Bio, the nonprofit statewide trade association that serves and promotes the life sciences industry in the Commonwealth. VEDP Interim President and CEO Jason El Koubi spoke with Newby about recent life sciences success stories in the Commonwealth and Virginia Bio’s efforts to grow the industry, including the recently announced industry hub, Virginia Bio-Connect.
TUSCON, AZ / ACCESSWIRE / April 5, 2022 / AURP, the leading nonprofit representing research parks, innovation districts and regional technology clusters, today announced a realignment of its executive team to optimize AURP’s continued success and global development strategies.
Vickie Palmer, current Director of Operations, has been appointed AURP CEO. Palmer assumes this executive leadership role following her 15 years of experience significantly expanding AURP’s membership and sponsorship community, plus overseeing AURP’s roster of events and programs. During her time with AURP, Palmer has led the organization’s membership, event management and overall operations while working closely with the organization’s CEO, Board of Directors and membership community.
OLATHE, Kan., April 06, 2022–(BUSINESS WIRE)–Innara Health, the industry leader in feeding development for newborns and infants born prematurely is collaborating with Cardinal Health on the redesign of the NTrainer System. The next generation NTrainer will be smaller, more intuitive, and easier to integrate into NICU feeding protocols.
“We are thrilled to have a globally recognized organization like Cardinal Health support Innara and the NTrainer. Not only is this collaboration validating for our clients and our team, but it is also a clear indication of Cardinal Health’s commitment to improving clinical outcomes through innovation. We look forward to seeing their contributions toward providing preterm infants with their best opportunity to develop, grow, and thrive,” stated Innara Health CEO Chris Mathia.
Adaptive Phage Therapeutics, Inc., a Gaithersburg, MD-based clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, raised $20m in further funding.
The AMR Action Fund has joined an existing $41m Series B round as a co-investor. The round was initiated in May 2021 and led by Deerfield Management Company, with participation from a second institutional investor and Mayo Clinic. Martin Heidecker, PhD, Chief Investment Officer of the AMR Action Fund, will join APT’s Board of Directors.
Image: https://www.finsmes.com
Three portfolio companies have graduated from the Germantown Innovation Center (GIC), Montgomery County’s business incubator program. The County’s incubator program started in 1999 to foster the growth and development of young technology companies. Akan Biosciences, Intelligent Fusion Technology and Seraxis are the three County-based companies graduating from the program this spring.
“Montgomery County continues to be the epicenter of bio health and information technology in the region,” said County Executive Marc Elrich. “Congratulations to Akan Bio, Intelligent Fusion Technology, and Seraxis on their graduation from our incubator. We are excited for their continued growth in the County. Montgomery County is committed to having an economic development environment that fosters growth and entrepreneurship, and these graduates are just the most recent example of the great work happening in our incubators and throughout the County.”
These free 1:1 virtual sessions are an opportunity to discuss your company with experts in diagnostics, therapeutics, digital health and medical devices. If you’re a growth-stage biohealth company looking for unbiased advice on your pitch deck, commercialization strategy, evidence development or entrepreneurial challenges, our EIRs can help.
To sign-up for any of the EIR dates in 2022, please follow this link.
GAITHERSBURG, Md., April 01, 2022 (GLOBE NEWSWIRE) — Altimmune, Inc., (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first subject in the 48-week Phase 2 MOMENTUM trial evaluating the safety and efficacy of pemvidutide1 in subjects with obesity or overweight. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and non-alcoholic steatohepatitis (NASH). The Company also today announced the completion of enrollment in its 12-week Phase 1b clinical trial of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD).
